French national diagnosis and care protocol (PNDS) for infantile idiopathic hypercalcemia (IIH)

The objective of this study was to establish a French National Diagnosis and Care Protocol (PNDS: Protocole National de Diagnostic et de Soins), with the aim of providing health professionals with free, open access synthesis on optimal management and care of patients with Infantile Idiopathic Hypercalcemia (IIH) (https://www.has-sante.fr/jcms/p_3522489/fr/hypercalcemie-infantile-idiopathique-hii). The process involved a critical review of the literature and a multidisciplinary expert consensus. IIH is a rare genetic disorder, with a prevalence estimated at 1 in 33,000. Its clinical manifestations (such as urinary stones or nephrocalcinosis) can appear at different ages. The pathophysiology of IHH is characterized by excessive 1,25(OH)2 vitamin D mediated dietary digestive calcium absorption. The underlying mechanism varies depending on the pathogenic variant involved, which is located in one of two genes, CYP24A1 or SLC34A1. The natural history and pathophysiology of IHH remain poorly understood and are underreported in the literature. Management of the disease varies according to the presentation and severity of hypercalcemia. Non-specific management strategies encompass the cessation of calcium intake, the discontinuation of native vitamin D supplementation, hyperhydration, and the occasional utilization of bisphosphonates. The necessity for long-term treatment, which may encompass both non-specific measures and specific interventions, depends on the severity and the genetic variant identified. Long-term follow-up appears essential, although there is limited data available, particularly for detecting complications of the disease, with nephrocalcinosis being the primary one.

Authors

Institutions

Publication Details

Journal
Orphanet Journal of Rare Diseases
Published
2026-07-17
DOI
https://doi.org/10.1186/s13023-026-04483-3
Primary Topic
Bone health and treatments
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

French national diagnosis and care protocol (PNDS) for infantile idiopathic hypercalcemia (IIH)

Gilles Cambonie, Marie Courbebaisse, Elodie Adler, Jean‐Pierre Salles et al.
Orphanet Journal of Rare Diseases
Bone health and treatments
article

French national diagnosis and care protocol (PNDS) for infantile idiopathic hypercalcemia (IIH)

Gilles Cambonie, Marie Courbebaisse, Elodie Adler, Jean‐Pierre Salles, Barbara Girerd, Valérie Porquet‐Bordes, Cyril Amouroux, Odile Dicky, Fairouz Halitim, Guigonis, Anya Rothenbühler, Pascal Houiller, E. Marquant, Denis Morin, Yoan Le Goff, Justine Bacchetta, Jean Philippe Bertocchio, Agnès Linglart, Thomas Edouard
article en

Abstract

The objective of this study was to establish a French National Diagnosis and Care Protocol (PNDS: Protocole National de Diagnostic et de Soins), with the aim of providing health professionals with free, open access synthesis on optimal management and care of patients with Infantile Idiopathic Hypercalcemia (IIH) (https://www.has-sante.fr/jcms/p_3522489/fr/hypercalcemie-infantile-idiopathique-hii). The process involved a critical review of the literature and a multidisciplinary expert consensus. IIH is a rare genetic disorder, with a prevalence estimated at 1 in 33,000. Its clinical manifestations (such as urinary stones or nephrocalcinosis) can appear at different ages. The pathophysiology of IHH is characterized by excessive 1,25(OH)2 vitamin D mediated dietary digestive calcium absorption. The underlying mechanism varies depending on the pathogenic variant involved, which is located in one of two genes, CYP24A1 or SLC34A1. The natural history and pathophysiology of IHH remain poorly understood and are underreported in the literature. Management of the disease varies according to the presentation and severity of hypercalcemia. Non-specific management strategies encompass the cessation of calcium intake, the discontinuation of native vitamin D supplementation, hyperhydration, and the occasional utilization of bisphosphonates. The necessity for long-term treatment, which may encompass both non-specific measures and specific interventions, depends on the severity and the genetic variant identified. Long-term follow-up appears essential, although there is limited data available, particularly for detecting complications of the disease, with nephrocalcinosis being the primary one.

Orphanet Journal of Rare Diseases
Université Claude Bernard Lyon 1 (FR), Centre National de la Recherche Scientifique (FR), Inserm (FR), Université Fédérale de Toulouse Midi-Pyrénées (FR), Université de Montpellier (FR), Université Paris Cité (FR), Université Paris-Saclay (FR), Centre Hospitalier Universitaire de Toulouse (FR), Sorbonne Université (FR), Hôpital Femme Mère Enfant (FR), Institut Necker Enfants Malades (FR), Centre de Recherche des Cordeliers (FR), Institut de Recherche et de Documentation en Économie de la Santé (FR), Centre Hospitalier Universitaire de Montpellier (FR), Assistance Publique – Hôpitaux de Paris (FR), Pitié-Salpêtrière Hospital (FR), Metabolism and Renal Physiology (FR), Montpellier Business School (FR), Physiopathologie, diagnostic et traitements des maladies musculo-squelettiques (FR), ERN GUARD-Heart (NL), Hôpital Arnaud de Villeneuve (FR), Hôpital de la Timone (FR), Bicêtre Hospital (FR), Université de Limoges (FR)
Direction Générale de l’offre de Soins
Openalex Percentile: Top 11%
Bone health and treatments
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.